Aquestive Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $27.00K, a 285.71% increase year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.00K.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $339.00K, a 75.65% increase year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $7.00K.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.27M, a 73.50% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $732.00K, a 73100.00% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.00K.
- Aquestive Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $2.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $27.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $1.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $1.27M 10-K · filed 2026-03-04 | |
| 2025-09-30 | $339.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $7.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $732.00K 10-K · filed 2026-03-04 | |
| 2024-09-30 | $193.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $539.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $1.00K 10-K · filed 2025-03-05 | |
| 2023-09-30 | $1.00K 10-Q · filed 2024-11-04 | |
| 2020-12-31 | $2.00K 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |